|View printer-friendly version|
|December 21, 2004 5:26 p.m.|
|Teva Board Of Directors Increases Repurchase Program To Up To $600 Million Of Teva Securities|
Jerusalem, Israel, December 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its Board of Directors has increased its repurchase program to authorize the Company to purchase up to an aggregate of $600 million of Teva securities, up from the $300 million previously authorized on September 3, 2004. The authorized amount includes approximately $180 million expended under the previous authorization on Teva's ADRs, ordinary shares and convertible debentures.